Adaptive Biotechnologies Corp

ADPT

Adaptive Biotechnologies Corp

ADPT

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):3,176,246

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:144,029,951Shares Outstanding:155,521,048Institutional Ownership Pct.:92.61%

Earnings Market Reaction:

Filing Date:2026-05-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	78	70	55	43	51	48	38	60	71	65	89	109
Available For Sale Securities Debt Securities Curr…	141	156	158	155	143	174	205	232	238	281	282	308
Accounts Receivable Net Current	48	50	45	44	44	42	41	36	42	38	31	32
Inventory Net	11	10	10	8	9	8	12	13	13	14	19	19
Prepaid Expense And Other Assets Current	14	13	14	11	11	11	12	11	10	11	13	9
Assets Current	292	300	281	262	256	284	308	352	374	410	435	477
Assets Noncurrent
Property Plant And Equipment Net	31	34	37	41	44	49	51	55	65	68	77	79
Operating Lease Right Of Use Asset	40	41	42	43	44	46	47	49	51	52	75	77
Available For Sale Securities Debt Securities Nonc…	19	13	4	24	39	34	24	-	-	-	-	-
Restricted Cash Noncurrent	3	3	3	3	3	3	3	3	3	3	3	3
Finite Lived Intangible Assets Net	1	2	2	3	3	3	4	4	5	5	6	6
Goodwill	119	119	119	119	119	119	119	119	119	119	119	119
Other Assets Noncurrent	1	1	2	2	2	2	3	3	3	4	3	3
Assets	506	513	491	497	511	539	559	585	620	661	718	765
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	10	6	10	7	6	7	7	10	12	8	4	9
Accrued Liabilities Current	7	8	7	7	8	8	6	7	8	9	10	8
Employee Related Liabilities Current	6	17	13	10	6	16	12	10	6	14	11	11
Operating Lease Liability Current	9	9	9	10	10	10	10	10	10	9	9	9
Contract With Customer Liability Current	49	45	41	55	55	56	52	52	47	49	55	58
Long Term Debt Current	6	5	2	3	2	1	-	-	-	-	3	-
Liabilities Current	87	90	83	92	88	98	88	88	83	88	93	95
Liabilities Noncurrent
Operating Lease Liability Noncurrent	69	70	72	74	76	79	82	84	87	89	92	94
Contract With Customer Liability Noncurrent	1	1	1	20	25	27	33	39	44	45	44	51
Long Term Debt Noncurrent	125	127	129	130	132	132	133	132	132	131	127	-
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	-	-	-	-
Liabilities	282	288	286	317	321	337	335	343	346	353	356	369
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,600	1,582	1,554	1,539	1,524	1,506	1,493	1,480	1,467	1,453	1,437	1,422
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	0	-0	-0	0	-0	-1
Retained Earnings Accumulated Deficit	-1,383	-1,363	-1,350	-1,359	-1,334	-1,304	-1,270	-1,238	-1,192	-1,144	-1,075	-1,025
Stockholders Equity	224	225	204	180	190	202	224	241	275	308	362	396
Minority Interest	8	6	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Liabilities And Stockholders Equity	506	513	491	497	511	539	559	585	620	661	718	765
Debt Securities Available For Sale Amortized Cost …	141	156	158	155	143	174	205	232	238	281	283	309
Debt Securities Available For Sale Amortized Cost …	19	13	4	24	39	34	24	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	340	340	340	340	340	340	340	340	340	340	340	340
Common Stock Shares Issued	160	154	153	152	152	148	148	147	147	145	145	145
Shares Outstanding	160	154	153	152	152	148	148	147	147	145	145	145

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	9.94%	52.10%	-	-	-	-	-	-	-	-	-	-
2025	21.33%	41.03%	41.17%	19.28%	19.64%	55.84%	11.77%	-5.06%	5.46%	-17.50%	-12.09%	-22.05%
2024	10.93%	16.40%	45.02%	9.21%	4.49%	5.17%	5.51%	11.72%	41.92%	-5.31%	-2.47%	10.25%
2023	-	-	-	-22.61%	-36.31%	-48.24%	9.56%	14.22%	-7.93%	-21.17%	-41.61%	-12.17%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	3.35	3.34	3.38	2.84	2.92	2.89	3.52	3.99	4.51	4.66	4.67	5.00
Quick Ratio	3.06	3.08	3.09	2.63	2.70	2.69	3.24	3.72	4.23	4.37	4.31	4.71
Working Capital	204.80M	210.27M	198.07M	169.72M	168.68M	185.70M	220.72M	263.43M	291.08M	322.17M	341.94M	381.47M
Leverage & Debt
Debt to Equity	1.26	1.28	1.40	1.77	1.68	1.66	1.50	1.42	1.26	1.14	0.98	0.93
Interest Coverage TTM	-3.97	-4.85	-6.64	-10.31	-12.48	-14.04	-17.16	-17.66	-16.48	-16.45	-13.58	-16.67
Debt Ratio	0.56	0.56	0.58	0.64	0.63	0.62	0.60	0.59	0.56	0.53	0.50	0.48
Efficiency & Turnover
Asset Turnover TTM	0.58	0.53	0.48	0.38	0.34	0.30	0.28	0.25	0.25	0.22	0.22	0.24
Days Sales Outstanding TTM	56.77	60.68	61.83	71.05	82.43	81.28	74.14	72.62	76.34	83.63	58.66	53.19
Receivables Turnover TTM	6.43	6.01	5.90	5.14	4.43	4.49	4.92	5.03	4.78	4.36	6.22	6.86
Per Share Metrics
Diluted EPS TTM	-0.32	-0.39	-0.49	-0.80	-0.95	-1.08	-1.32	-1.45	-1.48	-1.56	-1.35	-1.32
Free Cash Flow Per Share TTM	-0.19	-0.32	-0.41	-0.54	-0.59	-0.67	-0.78	-0.93	-0.99	-1.16	-1.18	-1.18
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	75.26%	74.24%	71.84%	66.04%	62.53%	59.72%	58.46%	54.77%	57.06%	55.63%	59.64%	64.09%
Operating Profit Margin TTM	-15.82%	-20.62%	-30.93%	-59.02%	-75.66%	-90.83%	-112.69%	-129.23%	-125.27%	-133.33%	-108.61%	-100.01%
Net Profit Margin TTM	-16.80%	-21.47%	-31.49%	-59.06%	-74.82%	-89.12%	-110.13%	-126.50%	-123.26%	-132.29%	-109.10%	-100.74%
Growth Metrics
Net Revenue Growth (1Y)	55.87%	54.77%	42.57%	21.60%	8.61%	5.10%	-1.34%	-10.99%	-5.33%	-8.11%	6.93%	18.74%
Net Income Growth (1Y)	-65.00%	-62.72%	-59.24%	-43.23%	-34.07%	-29.19%	-0.41%	11.78%	10.15%	12.42%	-11.53%	-17.75%
EPS Growth (1Y)	-66.42%	-63.86%	-60.55%	-44.97%	-35.57%	-30.50%	-2.31%	9.49%	8.43%	10.96%	-12.62%	-18.91%
Valuation Metrics
P/E TTM	-43.49	-41.44	-28.65	-14.62	-7.82	-5.53	-3.87	-2.50	-2.18	-3.14	-4.02	-5.07
P/B TTM	9.63	10.95	11.16	9.87	5.82	4.36	3.38	2.21	1.70	2.29	2.18	2.45
P/S TTM	7.31	8.90	9.02	8.63	5.85	4.93	4.26	3.16	2.68	4.15	4.39	5.11
Market Cap	2.16B	2.46B	2.28B	1.77B	1.11B	881.87M	755.28M	533.64M	467.98M	707.48M	788.64M	968.91M
Enterprise Value	2.21B	2.52B	2.36B	1.86B	1.19B	967.23M	849.90M	605.90M	528.29M	773.07M	829.85M	859.67M
Calculated Values
Free Cash Flow TTM	-29.54M	-48.95M	-62.94M	-82.81M	-88.76M	-98.88M	-114.54M	-136.59M	-144.81M	-167.02M	-171.35M	-169.73M
Net Debt	52.97M	60.71M	76.80M	90.40M	82.92M	85.36M	94.62M	72.26M	60.31M	65.60M	41.21M	-109.24M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Benzeno, Sharon

Title: Chief Commercial Ofc Imm Med

Shares: 154,768

Price/Share: $21.14

Value: $3,271,795.52

Shares Owned: 221,278

Relationship: Officer

Ownership: Direct

2026-06-25Sale

Owner: Bobulsky, Susan

Title: Chief Commercial Officer, MRD

Shares: 5,000

Price/Share: $20.50

Value: $102,500.00

Shares Owned: 406,775

Relationship: Officer

Ownership: Direct

2026-06-25Sale

Owner: Griffin, Michelle Renee

Title: -

Shares: 52,084

Price/Share: $20.18

Value: $1,051,055.12

Shares Owned: 15,625

Relationship: Director

Ownership: Direct

2026-06-16Sale

Owner: Robins, Harlan S

Title: Chief Scientific Officer

Shares: 6,160

Price/Share: $18.01

Value: $110,941.60

Shares Owned: 1,405,898

Relationship: Officer

Ownership: Direct

2026-06-11Sale

Owner: Bobulsky, Susan

Title: Chief Commercial Officer, MRD

Shares: 5,000

Price/Share: $19.00

Value: $95,000.00

Shares Owned: 411,775

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	154,768	21.14	$3,271,795.52	221,278	4
2026-06-25	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	5,000	20.50	$102,500.00	406,775	4
2026-06-25	Griffin, Michelle Renee	Director	-	Direct	Sale	52,084	20.18	$1,051,055.12	15,625	4
2026-06-16	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	6,160	18.01	$110,941.60	1,405,898	4
2026-06-11	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	5,000	19.00	$95,000.00	411,775	4
2026-06-04	Lo, Francis	Officer	Chief People Officer	Direct	Sale	39,741	17.49	$695,070.09	250,934	4
2026-06-04	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	11,000	18.00	$198,000.00	416,775	4
2026-05-18	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	3,115	13.04	$40,619.60	256,725	4
2026-04-27	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,037	14.23	$270,896.51	377,802	4
2026-04-24	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	14.02	$267,221.20	382,132	4
2026-04-21	Rubinstein, Julie	Officer	President and COO	Direct	Sale	30,941	14.66	$453,595.06	395,146	4
2026-04-16	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	14.18	$270,270.80	408,160	4
2026-04-13	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	13.52	$257,691.20	421,174	4
2026-04-08	Lo, Francis	Officer	Chief People Officer	Direct	Sale	22,564	15.07	$340,039.48	271,154	4
2026-04-08	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	10,000	14.85	$148,500.00	1,512,058	4
2026-04-08	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	37,263	15.19	$566,024.97	2,180,518	4
2026-04-08	Rubinstein, Julie	Officer	President and COO	Direct	Sale	30,941	15.16	$469,065.56	434,188	4
2026-04-02	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	14.60	$278,276.00	447,202	4
2026-03-31	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	13.45	$256,357.00	455,878	4
2026-03-26	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	14.12	$269,127.20	468,892	4
2026-03-23	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	13.83	$263,599.80	481,906	4
2026-03-18	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	13.18	$251,210.80	494,920	4
2026-03-13	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,060	12.96	$247,017.60	507,934	4
2026-03-11	Griffin, Michelle Renee	Director	-	Direct	Sale	15,394	13.91	$214,130.54	15,625	4
2026-03-11	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	470,167	13.17	$6,192,099.39	2,301,113	4
2026-03-11	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	63,103	13.17	$831,066.51	272,751	4
2026-03-11	Lo, Francis	Officer	Chief People Officer	Direct	Sale	30,593	14.08	$430,749.44	291,374	4
2026-03-11	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	470,266	13.17	$6,193,403.22	1,522,058	4
2026-03-11	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	18,672	13.17	$245,910.24	259,840	4
2026-03-11	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	41,338	13.17	$544,421.46	427,775	4
2026-03-10	Rubinstein, Julie	Officer	President and COO	Direct	Sale	19,460	14.68	$285,672.80	643,471	4
2026-03-05	Lo, Francis	Officer	Chief People Officer	Direct	Sale	38,074	15.09	$574,536.66	321,967	4
2026-03-05	Rubinstein, Julie	Officer	President and COO	Direct	Sale	30,941	16.00	$495,056.00	575,235	4
2026-03-03	Griffin, Michelle Renee	Director	-	Direct	Sale	48,044	15.30	$735,073.20	15,394	4
2026-03-03	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	14,233	16.52	$235,129.16	1,155,291	4
2026-02-27	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	182,891	15.99	$2,924,427.09	2,276,354	4
2026-02-04	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	2,145	18.46	$39,596.70	216,637	4
2026-02-03	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	8,120	19.00	$154,280.00	1,179,524	4
2026-02-02	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	124,998	18.44	$2,304,963.12	2,459,245	4
2026-01-12	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	4,290	18.00	$77,220.00	216,637	4
2026-01-12	Lo, Francis	Officer	Chief People Officer	Direct	Sale	79,590	17.73	$1,411,130.70	315,978	4
2026-01-06	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	10,000	16.44	$164,400.00	1,222,312	4
2026-01-05	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	124,998	15.59	$1,948,718.82	2,584,243	4
2026-01-02	Lo, Francis	Officer	Chief People Officer	Direct	Sale	3,125	16.08	$50,250.00	315,978	4
2025-12-22	Lo, Francis	Officer	Chief People Officer	Direct	Sale	4,394	17.50	$76,895.00	315,978	4
2025-12-22	Lo, Francis	Officer	Chief People Officer	Direct	Sale	4,394	17.50	$76,895.00	315,978	4/A
2025-12-15	Lo, Francis	Officer	Chief People Officer	Direct	Sale	113,890	15.57	$1,773,267.30	315,978	4
2025-12-10	Hershberg, Robert	Director	-	Direct	Sale	22,968	16.00	$367,488.00	46,722	4
2025-12-04	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	12,604	16.85	$212,377.40	296,791	4
2025-12-04	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	10,000	16.61	$166,100.00	1,232,312	4
2025-12-01	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	124,998	18.94	$2,367,462.12	2,709,241	4
2025-11-28	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	162,820	19.50	$3,174,990.00	216,637	4
2025-11-21	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	308,477	16.91	$5,216,346.07	296,791	4
2025-11-17	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	238	14.05	$3,343.90	269,343	4
2025-11-12	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	1,867	15.00	$28,005.00	2,869,975	4
2025-11-10	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	10,000	14.82	$148,200.00	1,269,524	4
2025-05-16	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	1,929	8.89	$17,148.81	269,581	4/A
2025-05-01	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	68,412	7.35	$502,828.20	1,279,524	4
2025-03-24	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	1,698	9.00	$15,282.00	1,279,524	4
2025-03-13	Griffin, Michelle Renee	Director	-	Direct	Sale	36,291	7.19	$260,932.29	15,394	4
2025-03-12	Hershberg, Robert	Director	-	Direct	Sale	53,000	7.59	$402,270.00	69,690	4
2025-03-10	Neupert, Peter M	Director	-	Direct	Sale	10,000	7.05	$70,500.00	224,690	4
2025-03-06	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	102,218	7.64	$780,945.52	2,959,249	4
2025-03-06	Griffin, Michelle Renee	Director	-	Direct	Sale	15,664	7.94	$124,372.16	51,685	4
2025-03-05	Robins, Harlan S	Officer	Chief Scientific Officer	Direct	Sale	96,656	6.98	$674,658.88	1,279,524	4
2025-03-05	Rubinstein, Julie	Officer	President and COO	Direct	Sale	59,505	6.98	$415,344.90	588,249	4
2025-03-05	Lo, Francis	Officer	Chief People Officer	Direct	Sale	20,875	6.98	$145,707.50	332,846	4
2025-03-05	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	10,320	6.98	$72,033.60	269,010	4
2025-03-05	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	44,665	6.98	$311,761.70	392,723	4
2025-03-05	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	26,023	6.98	$181,640.54	347,238	4
2025-02-20	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	99,107	8.44	$836,463.08	2,576,701	4
2025-02-18	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	211,160	8.50	$1,794,860.00	2,576,701	4
2024-11-18	Piskel, Kyle	Officer	Chief Financial Officer	Direct	Sale	248	4.98	$1,235.04	154,330	4
2024-08-22	Taylor, Stacy L	Officer	SVP and General Counsel	Direct	Sale	26,922	4.50	$121,149.00	139,365	4
2024-03-05	Robins, Chad M	Director,Officer	CEO and Chairman	Direct	Sale	48,673	3.44	$167,435.12	2,576,701	4
2024-03-05	Peterson, Tycho	Officer	Chief Financial Officer	Direct	Sale	15,456	3.44	$53,168.64	531,553	4
2024-03-05	Piskel, Kyle	Officer	Principal Accounting Officer	Direct	Sale	7,727	3.43	$26,503.61	123,318	4
2024-03-05	Lo, Francis	Officer	Chief People Officer	Direct	Sale	14,700	3.44	$50,568.00	253,745	4
2024-03-05	Bobulsky, Susan	Officer	Chief Commercial Officer, MRD	Direct	Sale	12,991	3.44	$44,689.04	248,290	4
2024-03-05	Taylor, Stacy L	Officer	SVP and General Counsel	Direct	Sale	13,381	3.44	$46,030.64	166,287	4
2024-03-05	Rubinstein, Julie	Officer	President	Direct	Sale	39,070	3.50	$136,745.00	472,754	4
2024-03-05	Benzeno, Sharon	Officer	Chief Commercial Ofc Imm Med	Direct	Sale	29,390	3.44	$101,101.60	327,415	4
2023-11-16	Piskel, Kyle	Officer	Principal Accounting Officer	Direct	Sale	259	4.13	$1,069.67	87,305	4
2023-08-08	Sood, Nitin	Officer	Chief Commercial Officer, MRD	Direct	Sale	10,550	6.54	$68,997.00	214,808	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.61%

Inst. Shares: 144,029,951

Shares Outstanding: 155,521,048

2025-12-31

93.01%

Inst. Shares: 141,123,757

Shares Outstanding: 151,721,939

2025-09-30

93.01%

Inst. Shares: 141,777,263

Shares Outstanding: 152,432,307

2025-06-30

95.54%

Inst. Shares: 145,292,209

Shares Outstanding: 152,082,284

2025-03-31

100.90%

Inst. Shares: 150,538,324

Shares Outstanding: 149,195,028

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	144,029,951	155,521,048	92.61%
2025-12-31	141,123,757	151,721,939	93.01%
2025-09-30	141,777,263	152,432,307	93.01%
2025-06-30	145,292,209	152,082,284	95.54%
2025-03-31	150,538,324	149,195,028	100.90%
2024-12-31	141,289,870	147,101,648	96.05%
2024-09-30	141,408,601	147,516,398	95.86%
2024-06-30	147,630,282	147,414,095	100.15%
2024-03-31	141,225,156	145,787,527	96.87%
2023-12-31	141,536,612	144,383,294	98.03%
2023-09-30	136,988,483	144,704,868	94.67%
2023-06-30	131,915,532	144,397,693	91.36%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Adaptive Biotechnologies Corp (ADPT) — SEC Financial Statements & Analysis

Adaptive Biotechnologies Corp (ADPT) is a biological products, (no diagnostic substances) company, incorporated in WA. Adaptive Biotechnologies Corp trades on ADPT: Nasdaq as: ADPT. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Adaptive Biotechnologies Corp reported a 55.87% year-over-year revenue growth, a Gross Profit Margin of 75.26% (TTM), a Debt-to-Equity ratio of 1.26x, a Price-to-Sales (P/S) ratio of 7.31x (TTM), a Price-to-Book (P/B) ratio of 9.63 (TTM), at a market cap of $2.16B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 55.87%
Gross Profit Margin TTM: 75.26%
Debt To Equity: 1.26x
P/S TTM: 7.31x
P/B TTM: 9.63
Market Cap: $2.16B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Adaptive Biotechnologies Corp in?

Adaptive Biotechnologies Corp (ADPT) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ADPT's market cap?

Adaptive Biotechnologies Corp (ADPT) has a market capitalization of $2.16B as of 2026-03-31.

What exchange does ADPT trade on?

Adaptive Biotechnologies Corp (ADPT) trades on the ADPT: Nasdaq.

Where is Adaptive Biotechnologies Corp incorporated?

Adaptive Biotechnologies Corp is incorporated in WA.

Adaptive Biotechnologies Corp (ADPT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.